MaxOne

MaxWell Biosystems is a Swiss life science tools company developing and commercializing high-density microelectrode array electrophysiology platforms for neuroscience research and preclinical drug discovery. Its products, including the MaxOne single-well system and MaxTwo multi-well system, enable high-resolution recording and stimulation of electrogenic cells such as neurons, organoids, retina, and brain slices. The company positions its technology as a way to support disease modeling, pharmacology and toxicology studies, phenotype screening, and neurocomputing workflows. Founded in 2016 as an ETH Zurich spin-off, MaxWell Biosystems serves academic, biotech, and pharma customers globally. The business is not a therapeutic drug developer; it is a commercial platform and instrumentation company supporting human health research.